Phospholipase A\textsubscript{2} Isolated from the Venom of *Crotalus durissus terrificus* Inactivates *Dengue virus* and Other Enveloped Viruses by Disrupting the Viral Envelope

Vanessa Danielle Muller\textsuperscript{1}*\textsuperscript{,} Ricardo Oliveira Soares\textsuperscript{3}, Nilton Nascimento dos Santos-Junior\textsuperscript{1}, Amanda Cristina Trabuco\textsuperscript{1}, Adelia Cristina Cintra\textsuperscript{2}, Luiz Tadeu Figueiredo\textsuperscript{4}, Antonio Caliri\textsuperscript{3}, Suely Vilela Sampaio\textsuperscript{2}, Victor Hugo Aquino\textsuperscript{1}\textsuperscript{a}

\textsuperscript{1}Laboratório de Virologia, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil, \textsuperscript{2}Laboratório de Toxinologia, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil, \textsuperscript{3}Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil, \textsuperscript{4}Centro de Pesquisa em Virologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brasil

Abstract

The *Flaviviridae* family includes several virus pathogens associated with human diseases worldwide. Within this family, *Dengue virus* is the most serious threat to public health, especially in tropical and sub-tropical regions of the world. Currently, there are no vaccines or specific antiviral drugs against *Dengue virus* or against most of the viruses of this family. Therefore, the development of vaccines and the discovery of therapeutic compounds against the medically most important flaviviruses remain a global public health priority. We previously showed that phospholipase A\textsubscript{2} isolated from the venom of *Crotalus durissus terrificus* was able to inhibit *Dengue virus* and *Yellow fever virus* infection in Vero cells. Here, we present evidence that phospholipase A\textsubscript{2} has a direct effect on *Dengue virus* particles, inducing a partial exposure of genomic RNA, which strongly suggests inhibition via the cleavage of glycerophospholipids at the virus lipid bilayer envelope. This cleavage might induce a disruption of the lipid bilayer that causes a destabilization of the E proteins on the virus surface, resulting in inactivation. We show by computational analysis that phospholipase A\textsubscript{2} might gain access to the lipid bilayer through the pores found on each of the twenty 3-fold vertices of the E protein shell on the virus surface. In addition, phospholipase A\textsubscript{2} is able to inactivate other enveloped viruses, highlighting its potential as a natural product lead for developing broad-spectrum antiviral drugs.

Introduction

The *Flaviviridae* family includes several virus pathogens associated with human diseases worldwide. Clinical conditions can vary from febrile or hemorrhagic diseases for *Dengue virus* (DENV) and *Yellow fever virus* (YFV), encephalitis for *Saint Louis encephalitis virus* (SLEV), *Japanese encephalitis virus* (JEV), *Tick-borne encephalitis virus* (TBEV), West Nile virus (WNV), and *Rocio virus* (ROCV) to hepatitis for *Human hepatitis C virus* (HCV) and *Human pegivirus* (HPgV). Currently, preventative vaccines for humans are available only for YFV, TBEV, and JEV and specific antiviral treatment only for HCV [1]. Therefore, the development of vaccines and the discovery of therapeutic compounds against the medically most important flaviviruses remain a global public health priority [2].

Of the diseases caused by viruses of the *Flaviviridae* family, dengue is a major threat to public health. It is estimated that 390 million dengue infections occur per year, with 100 million manifesting some type of symptoms [3] and approximately two million requiring hospitalization [4-6]. The major goal of anti-DENV therapy is to prevent patients from developing the severe forms of the disease [7].

Members of the *Flaviviridae* family include viruses with a positive-sense, single-stranded RNA genome of approximately 11,000 nucleotides, surrounded by a nucleocapsid and covered by a lipid envelope in which viral glycoproteins are anchored. The RNA genome encodes a single polyprotein that is proteolytically
cleaved into three structural proteins (C-prM/M-E) and seven non-structural proteins (NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) [8].

Natural products offer a huge amount of compounds with a great diversity of chemical structures, the result of biosynthetic processes that have been modulated over millennia through evolution. Natural products have served as important sources of drugs for medical purposes. Tubocurarine, a toxic alkaloid with skeletal muscle relaxant properties and obtained from the bark of the South American plant Chondrodendron tomentosum, was the first naturally occurring toxin used in medicine [9]. Since 1970, more than 40 drugs derived from natural products have been approved for use in humans [10–12]. Among natural products, venoms are complex mixtures of many different components, such as metalloproteinas, serine proteinases, potassium channel-blocking neurotoxins, proteolytic enzymes, cytotoxins, pre- and post-synaptic neurotoxins, cardiotoxins, and phospholipase A2s, which can provide clues for designing therapeutically useful molecules [13]. Indeed, Ferreira et al. [14] provided a good example of the potential of snake venom components for successful drug development. These authors identified bradykinin-potentiating peptides from the Brazilian arrowhead viper Bothrops jararaca venom that were used to develop an inhibitor (capotril) of the angiotensin-converting enzyme that is widely used as an anti-hypertensive agent [15]. Two other drugs, Tirofiban and Eptifibatide, were designed based on snake venom components and are available in the market as antiplatelet agents [16,17]. In addition, snake venoms and their components have shown antiviral activity against Measles virus [18], Sendai virus [19], Dengue virus [20,21], and Human immunodeficiency virus (HIV) [22]. One of the main components of snake venom is secreted phospholipase A2 (sPLA2), which has shown systemic toxicities that [22]. One of the main components of snake venom is secreted phospholipase A2 (sPLA2), which has shown systemic toxicities that have been modulated over millennia through evolution. One of the main components of snake venom is secreted phospholipase A2 (sPLA2), which has shown systemic toxicities that have been modulated over millennia through evolution. One of the main components of snake venom is secreted phospholipase A2 (sPLA2), which has shown systemic toxicities that [22]. One of the main components of snake venom is secreted phospholipase A2 (sPLA2), which has shown systemic toxicities that

**Materials and Methods**

**Cells and viruses**

VERO E6 (African green monkeys kidney epithelium cell line) [34] and C6/36 (Aedes albopictus mosquito cell line) [35] cells were maintained in Leibovitz’s medium (L-15) with 10% fetal bovine serum (FBS) at 37°C and 28°C, respectively. DENV-2 (NGC strain), Rocio virus (SPH 34675 strain), Mayaro virus (BeAn 243 strain), and Oropouche virus (BeAn 19991 strain) from the virus collection of the Virology Research Center of the Medical School of Ribeirão Preto, University of Sao Paulo, were used in this study. Enterovirus Cosacckie-B5 virus was kindly provided by Prof. Dr. Eurico Arruda Neto from the Viral Pathogenesis laboratory at the Virology Research Center, Medical School of Ribeirão Preto, University of Sao Paulo. Virus titration was performed in the Vero E6 cell line using the plaque assay, and the titer was expressed in plaque-forming units per milliliters (PFU/mL), as previously described [21].

**Dengue virus RNA detection and quantification: Quantitative real-time RT-PCR (qRT-PCR)**

Viral RNA detection was carried out by real-time RT-PCR using the SuperScript III Platinum SYBR Green One-Step qRT-PCR kit (Invitrogen, USA), as previously described [36]. Briefly, the 25-μL reaction mixture contained 0.5 μL of SuperScript III RT Platinum Taq Mix, 0.2 mM of each primer, 12.5 μL of 2× SYBR Green, and 5 μL of purified RNA. The amplification program was as follows: 30°C for 20 min for reverse transcription, 95°C for 5 min for reverse transcriptase inhibition and Taq DNA polymerase activation, followed by 45 cycles of PCR amplification with denaturation at 95°C for 15 sec, annealing at 60°C for 40 sec, and extension at 72°C for 30 sec. Finally, to verify the specificity of the PCR products, a melting curve was constructed by incubating the amplification products from 60°C to 90°C with an increase of 0.2°C/sec. The melting temperature (Tm) values of the specific amplicons were in the range of 80.57°C–81.73°C. For viral load determination, a standard curve was constructed using RNA transcribed in vitro from a plasmidial clone containing a fragment of 2500 base pairs (bp) corresponding to the 5’ end of DENV-3 strain D3BR/KP1/2003 [37]. This plasmid was prepared as follows: the 2500-bp fragment was amplified by RT-PCR and inserted into the plasmid pXL (Invitrogen, USA), which was used to transform Escherichia coli. An aliquot of 250 μL of the bacteria was inoculated into 10 mL of LB-ampicillin medium, followed by incubation at 37°C for 14 h with shaking. The plasmid was purified using the QIAGEN Plasmid Mini Kit (Qiagen, Germany) following the manufacturer’s recommendations. The plasmid was linearized by digestion with Bam HI, subjected to electrophoresis through a 1% agarose gel, and purified from the gel using the QIAquick Gel Extraction Kit (Qiagen, Germany) following the manufacturer’s specifications. For RNA preparation, 1 μg of the linearized plasmid was transcribed using RNAmaxx High Yield Transcription Kit (Stratagene, USA) following the manufacturer’s specifications. The cDNA was digested using RQ Dnase (Promega, USA) at 37°C for 20 min. After this, the RNA was purified using the QIAamp Viral RNA Kit (QIAGEN, Germany), and the concentration was determined by spectrophotometry at 260 nm. Based on the concentration and size of the RNA product (2500 bp), the copy number equivalent to the genomic RNA was calculated. Serial decimal dilutions of this RNA were prepared to construct the standard curve by real-time RT-PCR for determination of the virus titer, which was expressed in copy numbers per milliliters.

**Venom and toxin purification from Crotalus durissus terrificus**

Snake venom was obtained from the serpentarium of the Medical School of Ribeirão Preto, University of Sao Paulo (authorization of the Instituto Brasileiro do Meio Ambiente e dos Recursos Naturais Renovaveis, IBAMA: 1/35/1998/000846-1). Purification and evaluation of the enzymatic activity of PLA2-CB and crotoxin were carried out as previously described [21].

**Antiviral assays of PLA2-CB and crotoxin against DENV-2**

**Virucidal assay: virus treatment before infection.** To evaluate the direct effect of PLA2-CB and crotoxin on viral particles, DENV-2 (2 × 10^5 PFU) was incubated with non-cytotoxic concentrations (8, 4, and 0.004 ng/μL) of PLA2-CB and crotoxin in a final volume of 100 μL for 1 h at 37°C [21]. DENV-2 incubated with PBS was used as a control. The mixtures were diluted 100 times with L-15 serum-free medium and added to
VERO E6 cells seeded in 24-well plates (2×10^5 cells/well). After dilution, two concentrations (0.008 and 0.004 ng/μL) were above and one bellow (0.000004 ng/μL) the effective concentration that inhibits 50% (EC_{50}) of cell infection found in our previous study (EC_{50} of 0.000005 for PLA_{2}-CB and 0.001 for crotoxin) [21]. After 1 h of incubation at 37°C, the supernatant was removed, and 1 mL of L-15 medium supplemented with 2% fetal bovine serum (FBS) was added to the cells, followed by a further incubation at 37°C for 72 h. The cell culture supernatants were collected for viral inhibition evaluation by qRT-PCR, as mentioned above.

Pre-treatment assay: Treatment of cells with toxins before virus infection. This assay was carried out to evaluate whether the toxins could protect VERO E6 cells against viral infection. VERO E6 cells were seeded (2×10^5 cells/well) in a 24-well plate and incubated at 37°C for 24 h. The medium was then removed, and the cells were incubated with several concentrations of PLA_{2}-CB or crotoxin (0.000004, 0.04, 0.08, 0.5, 1, and 2 ng/μL). After 1 h of incubation, the supernatant was removed, and the cells were washed five times with PBS at room temperature. The cells were infected with 25–100 PFU of DENV-2 in 400 μL of L-15 for 1 h. The supernatant was removed, and 1 mL of L-15 supplemented with 2% FBS was added to the cells. After 72 h of incubation at 37°C, the cell supernatants were collected for viral RNA extraction using AxyPrep Body Fluid Viral DNA/RNA Miniprep Kit (Axygen, USA) following the manufacturer’s recommendations. Virus inhibition was evaluated by qRT-PCR, as mentioned above.

Evaluation of DENV-2 RNA exposure induced by PLA2-CB and crotoxin
This assay was carried out as previously proposed [38]. DENV-2 (2.0×10^5 PFU) was incubated with 8 ng/μL of PLA_{2}-CB, 8 ng/μL of crotoxin, 1 μg/μL of proteinase K (Life Technologies, USA), 1% Triton X-100 (Life Technologies, USA), or PBS in a total volume of 100 μL for 1 h and 2 h at 37°C. Then, the virus was treated with PBS or RNase A (Promega, USA) according to the manufacturer’s recommendation. RNA purified from DENV-2 (2.0×10^5 PFU) was used as a control for RNA degradation induced by RNase A. After 1 h at 37°C, the viral RNA was extracted using AxyPrep Body Fluid Viral DNA/RNA Miniprep Kit (Axygen, USA), and RNA degradation was evaluated by qRT-PCR as mentioned above.

Virucidal assay of PLA2-CB and crotoxin against other enveloped and non-enveloped viruses
The enveloped viruses Dengue virus type 2, Rocio virus, Mayaro virus, and Oropouche virus and the non-enveloped Coxsackie B5 virus were used in this experiment. The viruses (25–100 PFU) were incubated with serial decimal dilutions of PLA_{2}-CB and crotoxin (50, 5, 0.5, 0.005, 0.0005, and 0.00005 ng/μL) for 1 h at 37°C. The treated viruses were used to infect VERO E6 cells contained in a 24-well plate for 1 h. The supernatant was removed, and the cells were overlaid with 1 mL of L-15 supplemented with 2% FBS and 1.8% carboxymethylcellulose. After 7 days at 37°C, the semisolid overlay medium was removed, and the cells were fixed and stained with naphthol blue-black in 5% acetic acid for plaque counting. The treatment of each virus was repeated three times, and the concentration that inhibited 50% of plaque formation (Effective Concentration 50%, EC_{50}) was calculated by comparison with the number of plaques observed in the PBS-treated cells.

Steric and electrostatic analysis of the interaction of PLA2-CB with the lipid bilayer of the DENV envelope
The DENV external structural model was obtained from RCSB Protein Data Bank under the PDB ID: 3F53 [39]. This model was developed by Zhang et al. [40] by electron microscopy analysis and reflects the structure of DENV under physiological temperature (37°C), in accordance with the experiments conducted in this work. We used this electron microscopy structure as a model to reconstruct a more refined version of the virus structure, fitting 180 high-resolution copies of DENV-2 E protein (PDB ID: 1OAN) [41]. The DENV membrane patch used to reproduce the 3-fold pore environment in the electrostatic analyses was assembled with the CHARMM-GUI program [42] and further thermalized with the GROMACS Molecular Dynamics package [43]; the lipid composition follows that described by Zhang et al. [44]. The resolved PLA_{2}-CB crystal structure was obtained under PDB ID: 2QOG [45]. Because this model is built as a tetramer, we extracted one monomer (including the Ca^{2+} ion) with software Visual Molecular Dynamics – VMD [46], completing the missing atoms from residues Thr51 and Pro74 with the aid of the PS:Nmol plugin [47], and finally performed an adjustment with a potential energy minimization of the side chains with the GROMACS Molecular Dynamics package [43] using the IBM BlueGene/P supercomputer hosted at Rice University. For the all-atom MD with the explicit solvent [TIP3P water model [48] constrained by the SETTLE algorithm [49]], we used the CHARMM36 force-field [50] adapted to GROMACS by Piggo and colleagues, 2012 [51], with the Particle Mesh Ewald (PME) treatment for the electrostatic interactions among the atoms, with a cut-off of non-bonded interactions of 1.0 nm. The neutral pH of the system was emulated indirectly by fixing the protonation states of ionizable side chains at their correspondent pKa values, according to Nozaki and Tanford [52]. The temperature of the system was set to 310 K, and the pressure was maintained at 1 atm using the Nose-Hoover and Parrinello-Rahman algorithms, respectively [53–55]. The simulation protocol starts with potential energy minimizations with the steep descent method until the convergence of an energy threshold smaller than 2×10^{-6}kj mol^{-1} nm^{-1}. Maxwell-Boltzmann distribution assigns velocities to all atoms in the system according to the chosen initial temperature, and a position restriction was applied to the protein portion, allowing full solvation with the newly introduced water. After this step, we removed all restraints from the heavy atoms of the protein and used the P-LINCS algorithm [56] to constrain all bonded interactions, allowing us to set a time step of 2 femtoseconds. The electrostatic analyses and electrical field of the system consisting of one monomer of PLA_{2}-CB plus the extracted 3-fold pore from DENV were generated with the APBS (Adaptive Poisson-Boltzmann Solver) plugin [57] in the PyMol software [47]. The atomic individual charges of PLA_{2}-CB and the DENV 3-fold pore were attributed with aid of the pdb2pqr online server [58], and their protonation states were determined at pH 7.0 by PROPKA 3.1 [59]. The charges from the membrane atoms were calculated and assigned with the program editconf (-mead option) in the package GROMACS 4.5.5. In all cases, we set as default the solvent and protein/lipid dielectric constants to 78.0 and 2.0, respectively.

Statistics
A Mann–Whitney U test was used to compare the differences between the treated and untreated control groups. P values of < 0.05 were considered to indicate statistically significant differences. The statistical analyses were carried out using GraphPad Prism version 5.03 (GraphPad Software, La Jolla, CA).
Results

Evaluation of the direct action of PLA2-CB and crotoxin on the DENV-2 virion: Virucidal assay

To analyze whether PLA2-CB and crotoxin have a direct effect on the virus particle, DENV-2 (2.0 \times 10^3 PFU) was treated with 8, 4, and 0.0004 ng/mL of each toxin or PBS. One hour after treatment, the mixture was diluted 100 times (final concentration 0.08, 0.04, and 0.000004 ng/mL of toxins and 20 PFU of DENV-2) and then used to infect Vero cells. The purpose of the dilution was to reduce the concentration of toxins in contact with the cells and to use concentrations above (0.08 and 0.04 ng/mL) and below (0.000004 ng/mL) the EC50 found in our previous study [21]. Viral replication was evaluated in the cell culture supernatant after 72 h of infection by qRT-PCR. A significant inhibition of virus replication was observed when the virus was treated with 8 and 4 ng/mL of PLA2-CB and crotoxin in a dose-dependent manner, suggesting a direct action of the toxins on the virus particle (Figure 1). However, despite the low concentration of toxins, some effect on Vero cells that trigger an antiviral mechanism cannot be discarded.

Pre-treatment assay: Treatment of cells with toxins before virus infection

To better analyze whether PLA2-CB and crotoxin have some effect on Vero cells that influences DENV-2 inhibition, the cells were treated with several concentrations of PLA2-CB and crotoxin, including those used in the virucidal assay after dilution (0.000004, 0.04, 0.08, 0.5, 1, and 2 ng/mL), before infection. One hour after treatment, the cells were washed and infected with the same amount of DENV-2 used in the virucidal assay (20 PFU). The qRT-PCR analysis of the cell culture supernatant after 72 h of infection showed that virus replication was significantly inhibited only at the higher toxin concentrations, 1 and 2 ng/mL (Figure 2). This result strongly suggests that the antiviral effect of PLA2-CB and crotoxin observed in the virucidal assay was due to a direct action on the virus particle.

In vitro DENV-2 RNA exposure induced by PLA2-CB and crotoxin

The antiviral effect of toxins might be related to enzymatic activity by means of glycerophospholipid cleavage at the virus lipidic envelope, which could induce an exposure of the virus RNA genome. To investigate this hypothesis, DENV-2 was treated with 8 ng/µL of PLA2-CB and crotoxin for 1 and 2 hours at 37°C and then with RNase-A to evaluate RNA exposure. A significant viral RNA degradation was observed when DENV-2 was treated with PLA2-CB and crotoxin, suggesting virus RNA exposure (Figure 3). However, increased RNA degradation was observed when DENV-2 was previously treated with protease (protease K) or detergent (Triton X-100), both of which destroy the virus envelope and induce the complete exposure of genomic RNA (Figure 4). Therefore, the lower level of genomic RNA degradation observed after PLA2-CB or crotoxin treatment suggests a partial exposure of the virus RNA by the partial disruption of the virus envelope. Incubation of DENV-2 with toxins for more than 1 hour did not increase the viral RNA degradation, suggesting that all the available glycerophospholipid on the virus envelope were already cleaved in 1 hour.

Evaluation of PLA2-CB and crotoxin antiviral activity against other enveloped viruses

The above experiments suggested that PLA2-CB and crotoxin exert their antiviral functions via partial cleavage of the virus envelope, which has a cellular origin. Therefore, these toxins could also have an antiviral effect against other enveloped viruses. To test this hypothesis, we evaluated the antiviral activity of PLA2-CB and crotoxin, in a virucidal assay, against other enveloped viruses, Rocio virus (Flaviviridae family), Oropouche virus (Bunyaviridae family), and Mayaro virus (Togaviridae family) and the non-enveloped virus Coxsackie B5 virus (Picornaviridae family). As expected, the toxins showed a high antiviral effect (very low EC50) only against the enveloped viruses (Table 1, Figure S1–S8).

![Figure 1. Virucidal assay.](image-url)
Steric and electrostatic analysis of the interaction of PLA2-CB with the DENV envelope lipid bilayer

The results presented thus far consistently indicate an effective selectivity of PLA2-CB and crotoxin action in inhibiting enveloped viruses. By including structural analyses, we gained a more comprehensive knowledge of such selectivity and its process by outlining the implicated molecular mechanism of the PLA2-CB/crotoxin–DENV interaction. The results concerning the non-enveloped Coxsackie virus, in addition to the similar success rates shared between DENV and other enveloped viruses in virucidal assays, suggest a direct catalytic action on the phospholipid bilayer. In DENV, however, this structure is not fully exposed: it lies below the protein E shell, which must be surmounted by PLA2-CB to gain access to its substrate. At physiological temperature (37°C), Dengue virus assumes an expanded and mostly spherical configuration, whereby E protein sub-units are arranged in such a conformation that leads to an enhanced area of lipid envelope exposure [40]. Although essentially spherical, this configuration inherits the characteristic icosahedral symmetry from the more compact configuration at room temperature and can be described as a function of it. Three repeating sets of major gaps among the E proteins were identified in the 3-fold axis pores [60], the 5-fold axis pores, and the middle points among them (Fig. 5, a). However, cryo-electron microscopy analyses showed that the widest areas of exposure are those located on each of the twenty 3-fold axes [44]. These areas comprise the smaller radial distances from the center of the virus (~232 Å²), as opposed to the highest value of ~264 Å², indicating that these regions concentrate the deepest cavities on the virus surface. Combining the properties of this pronounced cavity with its aforementioned large diameter, it becomes clear that the 3-fold pore is indeed a remarkable site of exposure of the buried DENV lipid envelope. The planar surface that surrounds the active site (i-face) from the bovine group-IB (bGIB) PLA2 has an area of approximately 1500 Å² [61]; because snake PLA2-CB shares a very similar structure with (bGIB) PLA2, we assume the same i-face area for both. By structural analysis, we estimated that the 3-fold pore has an area of at least approximately 2500 Å², being therefore at least 60% wider than a PLA2-CB monomer by superimposition at the planar orientation (Fig. 5, b). Such orientation is primarily based on taking full advantage of the interaction of the hydrophobic amino acids of PLA2-CB (highlighting Trp31, Trp70, Tyr73, and Phe119) with the hydrophobic matrix just below the level of the polar phospholipid heads in the zwitterionic DENV bilayer. Electrostatic analyses of the complex PLA2-CB/DENV 3-fold pore showed that the prominently positive inner surface of the 3-fold pore facing the negative charges of the membrane tends to establish a perpendicular electrical field to the plane of membrane around its periphery, whereas the centermost region displays a weaker electrical field (Fig. 5, c). We believe that because PLA2-CB displays a net positive surface charge, the particular setting of these fields could slightly repel it from the pore edges. The combined repulsion of the pore edges maintains PLA2-CB in the central more neutral field; at the same time, the membrane polarity could play an increasing attracting role as their distance reduces. Once PLA2-CB reaches the membrane, it establishes contact with the...
phospholipids, which are hydrolyzed, destabilizing the membrane and therefore the general integrity of the virus.

To further analyze if the virus external structure influence the antiviral activity of toxins, and considering that DENV acquire a “bumpy,” expanded conformation when incubated at 37°C as opposed to its smooth structure at room temperature [40], DENV-2 was incubated with toxins at 28°C (temperature used to infect the mosquito C6/36 cells) and 37°C and then treated with RNase (Figure 6). A significant higher RNA degradation was observed when DENV-2 was treated with PLA2-CB at 37°C, supporting the hypothesis that at this temperature the relaxed viral external structure allows an enhanced contact of PLA2-CB with the glycerophospholipid on the virus envelope. However, the level of RNA degradation was the same at both temperatures for crotoxin. The last result might be related to the heterodimeric nature of this toxin (PLA2-CB+crotapotin); crotapotin act as a chaperon that enhances PLA2-CB activity [62].

Discussion

In a previous study, we showed that PLA2s isolated from the venom of Crotalus durissus terrificus have a potent antiviral action against DENV-2 and YFV, especially at the early stage of the multiplication cycle [21]. Inhibition of the pathogen infectivity induced by PLA2 can occur by direct action on the pathogen or as alternative processes on the host or surrounding medium [63–65]. Here, we demonstrate a dose-dependent inhibition of DENV-2 infection in Vero cells induced by crotoxin and PLA2-CB in a virucidal assay, providing strong evidence of the direct action of these toxins on the virus particle. Crotoxin is a heterodimeric protein composed of the basic PLA2-CB and the acidic nontoxic catalytically inactive protein crotapotin, which act as a chaperon enhancing PLA2-CB activity [62]. Therefore, virus inhibition is most likely induced by the PLA2-CB enzymatic activity, which relies on the hydrolysis of the sn-2 acyl ester linkage of sn-3-glycerophospholipids, producing fatty acids and lysophospholipids as reaction products [66]. In accordance with this hypothesis, we have found previously, performing an virucidal assay, that PLA2-CB lost its antiviral activity in the absence of Ca++2, which is an essential cofactor for its enzymatic activity, or by the inhibition of the enzymatic activity, suggesting that its antiviral action is due to the glycerophospholipids cleavage on the virus envelope [67]. Glycerophospholipid hydrolysis would result in degradation of the virus envelope, leading to the exposure of the virus genomic RNA. The virus RNA degradation induced by RNase A after crotoxin and PLA2-CB treatment strongly supports this hypothesis. As degradation was considerably lower when compared to that induced by detergent (Triton X-100) and protease (protease K) treatments, these results suggest that PLA2-CB induces a partial envelope destabilization rather than full virus disassembly, in accordance with the PLA2-CB enzymatic function. This hypothesis is in agreement with the results obtained when Newcastle disease virus (NDV), an enveloped virus of the Paramyxoviridae family, was treated with PLA2s from different snakes [32]. NDV

| Virus                  | Toxin   | EC50 (ng/μL) | 95% confident limit (ng/μL) |
|------------------------|---------|--------------|-----------------------------|
| Dengue virus type 2    | PLA2-CB | 6.6E-5       | 2.56E-5-1.78E-4              |
|                        | Crotoxin| 0.0078       | 0.0042-0.015                 |
| Rocío virus            | PLA2-CB | 0.021        | 0.0095-0.048                 |
|                        | Crotoxin| 0.0046       | 0.0029-0.0074                |
| Mayaro virus           | PLA2-CB | 0.066        | 0.025-0.18                   |
|                        | Crotoxin| 0.0036       | 0.0012-0.011                 |
| Oropouche virus        | PLA2-CB | 0.0067       | 0.0023-0.019                 |
|                        | Crotoxin| 0.0054       | 0.0023-0.013                 |
| Coxsackie B5 virus     | PLA2-CB | -            |                             |
|                        | Crotoxin| -            |                             |

Antiviral activity of PLA2-CB and crotoxin against Dengue virus type 2, Rocío virus, Mayaro virus, Oropouche virus, and Coxsackie B5 virus.

doi:10.1371/journal.pone.0112351.t001
lost infectivity and cell fusing activity, which depends on envelope integrity, without significantly altering the hemagglutinin, hemolysin, or neuraminidase properties.

The fact that PLA2-CB inactivates DENV-2 via the cleavage of envelope glycerophospholipids, which are derived from host cell membranes [8], suggests that this enzyme could also exert some effect on other enveloped viruses, as we have already observed for Yellow fever virus [21]. This hypothesis was confirmed: PLA2-CB was able to inhibit other enveloped viruses such as Rocio virus from the same Flaviviridae family as DENV and YFV, Oropouche virus from the Bunyaviridae family, and Mayaro virus from the Alphaviridae family. Further support was revealed by the failure of the enzyme to inactivate the non-enveloped Coxsackie B5 virus from the Picornaviridae family.

The evidence that PLA2-CB inhibits virus infection via glycerophospholipid cleavage prompted us to determine how PLA2-CB gains access to the viral lipid-bilayer envelope if multiple copies of the E glycoprotein form a shell around it. A recent study about the extended configuration that DENV assumes at physiological temperatures revealed a series of gaps among the E proteins that provide an enhanced area of direct exposure of the virus lipid bilayer [40]. Although several channels can be identified on the E protein shell, allowing the communication between the virus lipid membrane and the environment, we focused on the pores found on each of the twenty 3-fold vertices of the virus surface. These pores, being the widest and deepest openings of the protein envelope, could provide the primary passageway for PLA2-CB monomers, which have been shown to be enzymatically active against glycerol-phospholipid substrates [68]. The size of the 3-fold axis pores with an area roughly twice as large as required by the enzyme’s catalytic interface, provides a steric advantage to the accessibility of both PLA2-CB and crotoxin. The crotoxin complex (PLA2-CB and crotapotin) dissociates upon interaction with the membrane, and only the PLA2-CB unit binds to the substrate [69]. Accordingly, the area of contact for catalysis to occur is considered to be the same for crotoxin and PLA2-CB, which explains their similar efficiencies in virus inhibition.

Although sPLA2s show similar activity to phospholipids composed of different fatty acids, they do have particular affinities with regard to the phospholipid headgroup [70]. In addition, PLA2-CB containing tryptophan in the lipid-binding surface display the highest activity toward zwitterionic lipids [70]. PLA2-CB (Trp31, Trp70) can reportedly act upon both phosphatidylethanolamine (PE) and phosphatidylcholine (lecithin - PC), two major components of the DENV envelope, approximately 30 and 60% molar, respectively [44]. Several studies also confirm that

![Figure 5. Structural analyses of DENV particle and PLA2-CB.](image)

**Figure 5. Structural analyses of DENV particle and PLA2-CB.**

- **a)** View of DENV at physiological temperature with one PLA2-CB molecule shown at the putative site of interaction. The triangle shows one unit of the icosahedral symmetry, with the 5-fold and 3-fold vertices and intermediary areas indicated with an asterisk. The E protein domains I, II, and III are colored red, yellow, and blue, respectively; exposed membrane patches are colored in purple.
- **b)** Detailed view of the PLA2-CB/DENV 3-fold pore complex. The green line marks the slab view on **c)**. **c)** Electric field lines of the PLA2-CB/DENV 3-fold pore complex; the pore domains are represented on both sides in green mesh surface, whereas PLA2-CB is located in the middle. Hydrophobic aromatic residues in the i-face are colored in orange; the Ca\(^{2+}\) ion is colored in light purple. The membrane is colored in purple; blue and red lines indicate the proximity of positive and negative charges, respectively.

doi:10.1371/journal.pone.0112351.g005

![Figure 6. Analysis of the exposure of DENV-2 RNA.](image)

**Figure 6. Analysis of the exposure of DENV-2 RNA.**

DENV-2 was first treated with PLA2-CB, crotoxin (8 ng/μL each) and PBS at 37°C and 28°C and then with RNase-A. Virus RNA degradation was evaluated by qRT-PCR. The data represent mean values ± standard deviations (SD) for three independent experiments. The asterisks indicate statistically significant differences among groups (*p* < 0.05).

doi:10.1371/journal.pone.0112351.g006
PLA₂-CB has a high affinity for lecithin-rich vesicles [71,72], which justifies its synonym: lecithinase A or phosphatidylethanolamine-2-acetylholade [73,74]. Furthermore, target membrane curvature has been attributed as an important modulating factor for PLA₂ hydrolytic efficiency: the higher the curvature, the higher the enzymatic rate. Ahyayauch et al. [75] found increasing phosphatidyl ethanolos-specific phospholipase C (PI-PLC) catalytic rates with decreasing curvature radii (increasing curvature) of unilamellar vesicles consisting of PI. Similarly, Berg et al. [76] showed that the fraction of total hydrolyzed substrate in the presence of the pig pancreatic PLA₂ changes from 50% to 71% as the size of unilamellar vesicles decreased. The results appear to be similar for venom phospholipases: Kensil and Dennis [77] described higher catalytic rates for cobra Naja naja naja PLA₂ on small unilamellar PC vesicles (SUVs), faster after initial rates than those observed for large (LUVs) and multilamellar vesicles (MLVs). Interestingly, these authors detected distinctly higher catalytic rates on LUVs and MLVs at a small temperature range around the thermotropic phase transition of PC, at which a mixture of both gel and liquid crystalline phases are detected in vesicle lipid organization. Such a coexistence of two or more states triggers uneven phase boundary effects, which are loosely considered defects [78]. By observing phase boundary effects in monolayers, Grainger et al. [79] proposed that these prominences can be classified as defects; indeed, they provide a preferential site of action for PLA₂-CB, as opposed to more homogeneous surface areas. Such preferential sites of action for PLA₂-CB are also detected at monolayer borders, sites where the pronounced curvature provides effects similar to those of a disordered lipid patch [80]. In fact, Ahyayauch et al. [75] attributed the enhancement of catalytic rates to a successful partial penetration of the enzyme into the membrane hydrophobic matrix, which is more effortlessly achieved in regions of higher curvature and/or general defects on the bilayer surface. The DENV particle structure meets several of these PLA₂ catalytic-enhancing conditions. Indeed, its diminutive size and spherical shape confer a relatively high curvature to its membrane (radius of curvature ~232 Å) [40], characterizing only a marginally larger vesicle than a typical SUV, which, as already stated, provides a high-affinity substrate for PLA₂ activity. Because of the described points of access to the bilayer on the DENV surface, PLA₂-CB is able to hydrolyze the outer phospholipid layer, most likely accumulating fatty acids (FAs) and lysophospholipids (LPLs) on the membrane; this, in turn, destabilizes the membrane to a point at which fundamental protein conformational changes should be impaired. Additionally, it is known that the accumulation of LPLs in a bilayer causes an enhancement on its permeability [81,82] and further activation of PLA₂ [83], an observable fact with critical consequences to a supporting structure, such as a viral envelope. These modifications of the membrane structure allegedly disrupt the lipid order and thus its active lipid crystalline state, which most likely unbalances fundamental parameters such as the diffusion of anchored E proteins as well as their foothold, destabilizing the virus and its infective capability. Moreover, these disturbances are likely to drive the membrane to a highly disordered state, at which regions of bilayer breakdown can give rise to RNA exposure, which we detected with RNase treatment and real-time RT-PCR.

In summary, we provide strong evidence that crotoxin and PLA₂-CB have a direct effect on Dengue virus particles, most provably by glycerophospholipid cleavage on the virus envelope, which would lead to disruption of the lipid bilayer and destabilization of the E proteins on the virus surface, with the consequence of inactivation. Crotoxin and PLA₂-CB most likely gain access to the Dengue virus lipid bilayer through the pores found on each of the twenty 3-fold vertices in the E protein shell on the virus surface. In addition, PLA₂-CB was able to inactivate other enveloped viruses, highlighting its potential as a natural product lead for the development of broad-spectrum antiviral drugs.

Supporting Information

Figure S1 EC₅₀ of crotoxin against DENV-2 in the virucidal assay. DENV-2 (25–100 PFU) was incubated with serial decimal dilutions of crotoxin (50, 5, 0.5, 0.005, 0.0005, and 0.00005 ng/mL) for 1 h at 37°C. The treated viruses were used to infect VERO E6 cells contained in a 24-well plate. The percentage of inhibition was calculated by the reduction of the number of plaques found in the infected cells in comparison with the number of plaques in the cells infected with the untreated virus. (TIF)

Figure S2 EC₅₀ of PLA₂-CB against DENV-2 in the virucidal assay. DENV-2 (25–100 PFU) was incubated with serial decimal dilutions of PLA₂-CB (50, 5, 0.5, 0.005, 0.0005, and 0.00005 ng/mL) for 1 h at 37°C. The treated viruses were used to infect VERO E6 cells contained in a 24-well plate. The percentage of inhibition was calculated by the reduction of the number of plaques found in the infected cells in comparison with the number of plaques in the cells infected with the untreated virus. (TIF)

Figure S3 EC₅₀ of crotoxin against ROCV in the virucidal assay. ROCV (25–100 PFU) was incubated with serial decimal dilutions of crotoxin (50, 5, 0.5, 0.005, 0.0005, and 0.00005 ng/mL) for 1 h at 37°C. The treated viruses were used to infect VERO E6 cells contained in a 24-well plate. The percentage of inhibition was calculated by the reduction of the number of plaques found in the infected cells in comparison with the number of plaques in the cells infected with the untreated virus. (TIF)

Figure S4 EC₅₀ of PLA₂-CB against ROCV in the virucidal assay. ROCV (25–100 PFU) was incubated with serial decimal dilutions of PLA₂-CB (50, 5, 0.5, 0.005, 0.0005, and 0.00005 ng/mL) for 1 h at 37°C. The treated viruses were used to infect VERO E6 cells contained in a 24-well plate. The percentage of inhibition was calculated by the reduction of the number of plaques found in the infected cells in comparison with the number of plaques in the cells infected with the untreated virus. (TIF)

Figure S5 EC₅₀ of crotoxin against MAYV in the virucidal assay. MAYV (25–100 PFU) was incubated with serial decimal dilutions of crotoxin (50, 5, 0.5, 0.005, 0.0005, and 0.00005 ng/mL) for 1 h at 37°C. The treated viruses were used to infect VERO E6 cells contained in a 24-well plate. The percentage of inhibition was calculated by the reduction of the number of plaques found in the infected cells in comparison with the number of plaques in the cells infected with the untreated virus. (TIF)

Figure S6 EC₅₀ of PLA₂-CB against MAYV in the virucidal assay. MAYV (25–100 PFU) was incubated with serial decimal dilutions of PLA₂-CB (50, 5, 0.5, 0.005, 0.0005, and 0.00005 ng/mL) for 1 h at 37°C. The treated viruses were used to infect VERO E6 cells contained in a 24-well plate. The percentage of inhibition was calculated by the reduction of the number of plaques found in the infected cells in comparison with the number of plaques in the cells infected with the untreated virus. (TIF)
Figure S7 EC50 of crotoxin against OROV in the virucidal assay. OROV (25–100 PFU) was incubated with serial decimal dilutions of crotoxin (50, 5, 0.5, 0.005, 0.0005, and 0.00005 ng/µL) for 1 h at 37°C. The treated viruses were used to infect VERO E6 cells contained in a 24-well plate. The percentage of inhibition was calculated by the reduction of the number of plaques found in the infected cells in comparison with the number of plaques in the cells infected with the untreated virus.

(TIF)

Figure S8 EC50 of PLA2-CB against OROV in the virucidal assay. OROV (25–100 PFU) was incubated with serial decimal dilutions of PLA2-CB (50, 5, 0.5, 0.005, 0.0005, and 0.00005 ng/µL) for 1 h at 37°C. The treated viruses were used to infect VERO E6 cells contained in a 24-well plate. The percentage of inhibition was calculated by the reduction of the number of plaques found in the infected cells in comparison with the number of plaques in the cells infected with the untreated virus.

(TIF)

References

1. Wendi A, Adhoute X, Castellani P, Ouほしい V, Ansaldi C, et al. (2014) Chronic hepatitis C: future treatment. Clin Pharmacol 6: 1–17.
2. Ray D, Shi PY (2006) Recent advances in flavivirus antiviral drug discovery and vaccine development. Recent Pat Antinfect Drug Discov 1: 45–55.
3. Bhatt S, Getting PW, Brady OJ, Mesina JP, Farlow AW, et al. (2013) The global distribution and burden of dengue. Nature 496: 504–507.
4. Hales S, de Wet N, Maimond J, Woodward A (2002) Potential effect of population and climate changes on global distribution of dengue fever: an empirical model. Lancet 360: 830–834.
5. Kyle JL, Harris E (2008) Global spread and persistence of dengue. Annu Rev Microbiol 62: 71–92.
6. Letson GW, Singhhasivanon P, Fernandez E, Abeyingshe N, Amador JJ, et al. (2010) Dengue virus trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas. Hum Vaccin 6: 802–809.
7. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, et al. (2013) Ten years of dengue drug discovery: Progress and prospects. Antiviral Research 100: 500–519.
8. Lindenbach B, Thiel H, Rice C (2007) Flaviviridae: the viruses and their replication. In: Knipe D, Howley P, editors. Fields Virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins. pp. 1101–1151.
9. KING H (1948) Curare alkaloids, constitution of dextro-tubocurarine chloride. J Chem Soc 174: 265–276.
10. Ganesan A (2008) The impact of natural products upon modern drug discovery. Curr Opin Chem Biol 12: 306–317.
11. Butler MS (2005) Natural products to drugs: natural product derived compounds in clinical trials. Nat Prod Rep 22: 162–195.
12. Butler MS (2008) Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 25: 475–516.
13. Bailey P, Wilce J (2001) Venom as a source of useful biologically active compounds. Curr Opin Chem Biol 12: 306–317.
14. Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, et al. (1971) Isolation of bradykinin-potentiating dipeptidyl peptidase II from bovine pancreas. J Biol Chem 246: 511–515.
15. Butler MS (2008) Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep 25: 475–516.
16. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, et al. (1991) Isolation, elucidation of structure, and synthesis. Biochemistry 10: 4033–4039.
17. Ferreira SH, Bartelt DC, Greene LJ (1970) Isolation of bradykinin-potentiating dipeptidyl peptidase II from bovine pancreas. J Biol Chem 246: 511–515.
18. Petricevich VL, Mendonça RZ (2003) Inhibitory potential of Crotalus durissus terrificus venom on measles virus growth. Toxicon 42: 143–153.
19. Borkow G, Ovadia M (1999) Selective lysis of virus-infected cells by cobra snake phospholipases A2. J Virol 73: 1377–1382.
20. Zhang XG, Mason PW, Dubovi EJ, Xu X, Bourne N, et al. (2009) Antiviral activities of Crotalus durissus terrificus venom phospholipases A2 from Viperus-Russelli (Russells Viper) Snake-Venom. Toxicon 22: 207–217.
21. Vidyawarath BS, Kini RM, Godwa TV (1989) Purification and Partial Biochemical-Characterization of an Edema Inducing Phospholipase-A2 from Viperus-Russelli (Russells Viper) Snake-Venom. Toxicon 26: 713–720.
22. Thwin MM, Gopalakrishnakone P, Yuen R, Tan CH (1995) A Major Lethal Factor of the Venom of Burmese Russel Viper (Daboia-Russel-Samiiens) - Isolation, N-Terminal Sequencing and Biological-Activities of Daboain. Toxicon 33: 63–76.
23. Mukherjee AK, Ghosal SK, Maity CR (1997) Lysosomal membrane stabilization by alpha-toxochelid against the damaging action of Vipera russellii daboia venom phospholipase A2. Cellular and Molecular Life Sciences 53: 152–155.
24. Ferard D, Lambeau G, Maurin T, Lefebvre JG, Doglio A (2001) A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol Immunol 38: 341–347.
25. Kim JO, Chakrabarti BK, Guha-Niyogi A, Louder MK, Mascola JR, et al. (2007) Lysis of human immunodeficiency virus type 1 by a specific secreted human phospholipase A2. J Virol 81: 1444–1450.
26. Misumi H, Masuda S, Kudo I, Murakami M (2006) Group V and X secretory phospholipase A2 prevents adenosinergic inflammation in mammalian cells. Biochem J 393: 97–106.
27. Kohn A, Klibansky C (1967) Studies on the inactivation of cell-fusing property of Newcastle disease virus by phospholipase A. Virology 31: 383–385.
28. DRAYTON HA (1961) Inactivation of Ross virus by phospholipase A. Nature 192: 896.
29. Yasumura Y, Kawakita Y (1963) Studies on SV40 in tissue culture-preliminary step for cancer research in vitro. Nihon rinsho 21: 15.
30. Igarashi A (1978) Isolation of a Singh's Aedes albopictus cell clone sensitive to Dengue and Chikungunya viruses. J Gen Virol 40: 351–344.
31. Santos HW, Poloni TR, Souza KP, Muller VD, Tremeschin F, et al. (2008) A simple one-step real-time RT-PCR for diagnosis of dengue virus infection. J Med Virol 80: 1426–1430.
32. Achong VH, Amatissio E, Goncalves PF, da Silva EV, Vasconcelos PPC, et al. (2006) Molecular epidemiology of dengue type 3 virus in Brazil and Paraguay, 2002–2004. American Journal of Tropical Medicine and Hygiene 75: 710–715.
33. Kapteijn J, De Burggraave T, Freyman M, Pastorino B, Alen MM, et al. (2010) A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother 54: 3267–3270.
34. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF, Brice MD, et al. (1977) The Protein Data Bank. A computer-based archival file for macromolecular structures. Eur J Biochem 5: 353–355.
35. Igarashi A (1978) Isolation of a Singh's Aedes albopictus cell clone sensitive to Dengue and Chikungunya viruses. J Gen Virol 40: 351–344.
36. Dos Santos HW, Poloni TR, Souza KP, Muller VD, Tremeschin F, et al. (2008) A simple one-step real-time RT-PCR for diagnosis of dengue virus infection. J Med Virol 80: 1426–1430.
37. Fenard D, Lambeau G, Maurin T, Lefebvre JG, Doglio A (2001) A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol Immunol 38: 341–347.
38. Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem 29: 1395–1405.
39. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF, Brice MD, et al. (1977) The Protein Data Bank. A computer-based archival file for macromolecular structures. Eur J Biochem 5: 353–355.
40. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF, Brice MD, et al. (1977) The Protein Data Bank. A computer-based archival file for macromolecular structures. Eur J Biochem 5: 353–355.
41. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF, Brice MD, et al. (1977) The Protein Data Bank. A computer-based archival file for macromolecular structures. Eur J Biochem 5: 353–355.
51. Piggot TJ, Pên˜eiro A´ , Khalid S (2012) Molecular Dynamics Simulations of
50. Klauda JB, Venable RM, Freites JA, O’Connor JW, Tobias DJ, et al. (2010)
49. Miyamoto S, Kollman PA (1992) Settle: An analytical version of the SHAKE
48. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983)
47. Delano W (2002) The PyMOL Molecular Graphics System. In: LLC DS, editor.
63. Samy RP, Gopalakrishnakone P, Stiles BG, Girish KS, Swamy SN, et al. (2012)
62. Hendon RA, Fraenkel-Conrat H (1971) Biological roles of the two components
61. Pan YH, Epstein TM, Jain MK, Bahnson BJ (2001) Five coplanar anion binding
59. Li H, Robertson AD, Jensen JH (2005) Very fast empirical prediction and
58. Hess B (2008) P-LINCS: A Parallel Linear Constraint Solver for Molecular
57. Hess B (2008) LINCS: A Linear Constraint Solver for Molecular Dynamics
56. Hess B (2008) PLINCS: A Parallel Linear Constraint Solver for Molecular
55. Hess B (2008) LINCS: A Linear Constraint Solver for Molecular Dynamics
54. Nose´ S (1984) A unified formulation of the constant temperature molecular
53. Parrinello M, Rahman A (1980) Crystal Structure and Pair Potentials: A
52. Nozaki Y, Tanford C (1967) Examination of titration behavior. In: CHW H,
51. Piggot TJ, Pên˜eiro A´ , Khalid S (2012) Molecular Dynamics Simulations of
50. Klauda JB, Venable RM, Freites JA, O’Connor JW, Tobias DJ, et al. (2010)
49. Miyamoto S, Kollman PA (1992) Settle: An analytical version of the SHAKE
48. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983)
47. Delano W (2002) The PyMOL Molecular Graphics System. In: LLC DS, editor.